Detalhe da pesquisa
1.
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 24(8): 1602-1609, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29501779